Suppr超能文献

研究方案:急性肺损伤患者改善护理(ICAP)研究。

Study protocol: The Improving Care of Acute Lung Injury Patients (ICAP) study.

作者信息

Needham Dale M, Dennison Cheryl R, Dowdy David W, Mendez-Tellez Pedro A, Ciesla Nancy, Desai Sanjay V, Sevransky Jonathan, Shanholtz Carl, Scharfstein Daniel, Herridge Margaret S, Pronovost Peter J

机构信息

Johns Hopkins University, 5th floor, 1830 East Monument Street, Baltimore, MD 21205, USA.

出版信息

Crit Care. 2006 Feb;10(1):R9. doi: 10.1186/cc3948.

Abstract

INTRODUCTION

The short-term mortality benefit of lower tidal volume ventilation (LTVV) for patients with acute lung injury/acute respiratory distress syndrome (ALI/ARDS) has been demonstrated in a large, multi-center randomized trial. However, the impact of LTVV and other critical care therapies on the longer-term outcomes of ALI/ARDS survivors remains uncertain. The Improving Care of ALI Patients (ICAP) study is a multi-site, prospective cohort study that aims to evaluate the longer-term outcomes of ALI/ARDS survivors with a particular focus on the effect of LTVV and other critical care therapies.

METHODS

Consecutive mechanically ventilated ALI/ARDS patients from 11 intensive care units (ICUs) at four hospitals in the city of Baltimore, MD, USA, will be enrolled in a prospective cohort study. Exposures (patient-based, clinical management, and ICU organizational) will be comprehensively collected both at baseline and throughout patients' ICU stay. Outcomes, including mortality, organ impairment, functional status, and quality of life, will be assessed with the use of standardized surveys and testing at 3, 6, 12, and 24 months after ALI/ARDS diagnosis. A multi-faceted retention strategy will be used to minimize participant loss to follow-up.

RESULTS

On the basis of the historical incidence of ALI/ARDS at the study sites, we expect to enroll 520 patients over two years. This projected sample size is more than double that of any published study of long-term outcomes in ALI/ARDS survivors, providing 86% power to detect a relative mortality hazard of 0.70 in patients receiving higher versus lower exposure to LTVV. The projected sample size also provides sufficient power to evaluate the association between a variety of other exposure and outcome variables, including quality of life.

CONCLUSION

The ICAP study is a novel, prospective cohort study that will build on previous critical care research to improve our understanding of the longer-term impact of ALI/ARDS, LTVV and other aspects of critical care management. Given the paucity of information about the impact of interventions on long-term outcomes for survivors of critical illness, this study can provide important information to inform clinical practice.

摘要

引言

一项大型多中心随机试验已证明,低潮气量通气(LTVV)对急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)患者具有短期死亡率获益。然而,LTVV和其他重症监护治疗对ALI/ARDS幸存者长期预后的影响仍不确定。改善ALI患者护理(ICAP)研究是一项多中心前瞻性队列研究,旨在评估ALI/ARDS幸存者的长期预后,特别关注LTVV和其他重症监护治疗的效果。

方法

来自美国马里兰州巴尔的摩市四家医院11个重症监护病房(ICU)的连续机械通气ALI/ARDS患者将被纳入一项前瞻性队列研究。在基线时以及患者在ICU住院期间,将全面收集暴露因素(基于患者、临床管理和ICU组织方面)。在ALI/ARDS诊断后的3、6、12和24个月,将使用标准化调查和测试评估包括死亡率、器官功能损害、功能状态和生活质量在内的结局。将采用多方面的保留策略,以尽量减少失访的参与者。

结果

根据研究地点ALI/ARDS的历史发病率,我们预计在两年内招募520名患者。这个预计样本量是已发表的任何关于ALI/ARDS幸存者长期预后研究样本量的两倍多,有86%的把握度检测到接受较高与较低LTVV暴露患者的相对死亡风险为0.70。预计样本量也足以评估各种其他暴露因素与结局变量之间的关联,包括生活质量。

结论

ICAP研究是一项新颖的前瞻性队列研究,它将在以往重症监护研究的基础上,增进我们对ALI/ARDS、LTVV以及重症监护管理其他方面长期影响的理解。鉴于关于干预措施对危重病幸存者长期结局影响的信息匮乏,本研究可为临床实践提供重要信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2697/1550857/43cbea25f99f/cc3948-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验